IC50 values of compounds 3a–h, 5a–d, and erlotinib against four cancer cell lines.
Comp. | Cell viability% | Antiproliferative activity IC50 ± SEM (nM) | ||||
---|---|---|---|---|---|---|
A-549 | MCF-7 | Panc-1 | HT-29 | Average (GI50) | ||
3a | 89 | 72 ± 7 | 69 ± 6 | 74 ± 7 | 74 ± 7 | 72 |
3b | 90 | 70 ± 6 | 67 ± 6 | 70 ± 6 | 71 ± 6 | 70 |
3c | 87 | 50 ± 5 | 46 ± 4 | 54 ± 5 | 52 ± 4 | 51 |
3d | 89 | 76 ± 7 | 74 ± 7 | 76 ± 7 | 77 ± 7 | 76 |
3e | 86 | 32 ± 3 | 31 ± 3 | 34 ± 3 | 34 ± 3 | 33 |
3f | 90 | 62 ± 6 | 59 ± 5 | 65 ± 6 | 64 ± 6 | 63 |
3g | 89 | 64 ± 6 | 60 ± 6 | 64 ± 6 | 66 ± 6 | 64 |
3h | 85 | 82 ± 8 | 78 ± 7 | 86 ± 8 | 82 ± 8 | 82 |
5a | 87 | 25 ± 2 | 23 ± 2 | 26 ± 2 | 26 ± 2 | 25 |
5b | 90 | 39 ± 4 | 35 ± 4 | 41 ± 4 | 40 ± 3 | 39 |
5c | 86 | 53 ± 5 | 49 ± 4 | 54 ± 5 | 55 ± 5 | 53 |
5d | 90 | 46 ± 4 | 42 ± 4 | 48 ± 4 | 48 ± 4 | 46 |
Erlotinib | ND | 30 ± 3 | 40 ± 3 | 30 ± 3 | 30 ± 3 | 33 |